This year, the EMJ GOLD team were live on the ground at EHA 2026 to speak with industry leaders about the latest developments shaping the future of haematology
Interview by Helena Bradbury
In this interview, hear from Aliya Omer, Vice President, Global Head, Haematology Franchise, AstraZeneca, as she discusses how advances in personalised medicine are influencing the treatment landscape for haematological malignancies.
Reflecting on the progress made in areas such as chronic lymphocytic leukaemia, follicular lymphoma and multiple myeloma, Omer explores the opportunities and challenges associated with emerging treatment approaches across the evolving haematology landscape.
The conversation covers a range of topics, including the potential of CAR-T cell therapy, the growing use of predictive tools and artificial intelligence in clinical decision-making and the role of adaptive treatment strategies in improving patient outcomes.
Omer also shares her perspective on the practical barriers that continue to affect patient care, including access to innovative therapies and the complexities associated with delivering advanced treatments across diverse healthcare systems.
Guest bio
Aliya Omer is Global Head, Haematology Franchise, AstraZeneca. In this role, she oversees global strategy and commercial activities across the company’s haematology portfolio.
Omer has more than 20 years of experience spanning the pharmaceutical, biotechnology and consumer healthcare sectors. Prior to her current position, she held a variety of leadership roles across commercial, strategic and operational functions. Trained as an engineer with a background in materials science and biomedical engineering, she began her career in research and development before moving into business leadership.
Alongside her work in haematology, Omer has a longstanding interest in leadership development and mentorship. She is also engaged in initiatives focused on improving collaboration across the healthcare ecosystem and addressing disparities in access to care. Her work centres on supporting the development and delivery of therapies for people living with haematological cancers.
